OneSource Specialty Pharma files BRSR for FY26
OneSource Specialty Pharma Limited has filed its Business Responsibility & Sustainability Report (BRSR) for FY26. The report covers ESG performance, detailing business activities focused on pharmaceutical manufacturing with 70.80% exports. It highlights a workforce of 1,200 employees and 1,089 workers, and robust employee well-being measures. The company addresses material ESG issues and maintains strong governance and grievance redressal mechanisms.
The filing of a Business Responsibility & Sustainability Report (BRSR) is a standard regulatory requirement for listed companies. While it provides transparency on ESG aspects, it does not typically involve immediate material financial or operational changes that would significantly impact the company's valuation or stock performance. Hence, the impact is considered low.
The announcement is a routine filing of a regulatory report (BRSR) and does not contain any specific financial performance indicators, strategic changes, or events that would significantly impact the company's stock price or market perception. Therefore, the sentiment is neutral.
OneSource Specialty Pharma Limited has submitted its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed pursuant to Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides comprehensive disclosures on the company's environmental, social, and governance (ESG) performance.
The BRSR details the company's corporate identity, registered and corporate office information, and contact details for queries regarding the report. It outlines the business activities, which are entirely focused on the manufacturing of pharmaceutical products, accounting for 100% of turnover. The company serves both domestic and international markets, with exports contributing 70.80% to its total turnover.
Regarding its workforce, OneSource Specialty Pharma reported 1,200 permanent employees and 1,089 workers as of the end of the financial year. The report also details the company's commitment to employee well-being, with 100% of permanent employees and workers covered by health and accident insurance. Furthermore, the company has implemented measures for maternity benefits, paternity benefits, and day-care facilities.
The report highlights the company's material ESG issues, including product quality assurance, corporate governance, customer advocacy, sustainable procurement, occupational health and safety, cybersecurity, and environmental stewardship. It outlines the risks and opportunities associated with these issues and the company's approach to managing them.
OneSource Specialty Pharma Limited has also emphasized its commitment to transparency and disclosures, with a robust grievance redressal mechanism in place for various stakeholder groups, including communities, investors, shareholders, employees, and customers. The company has taken steps to ensure compliance with national and international codes and certifications, such as UNGC, GxP standards, and ISO certifications for quality, environment, and occupational health and safety.
A plain-language summary of a public exchange filing by Onesource Specialty Pharma Limited. Read the original for the full detail.